Are HTLA Antibodies Clinically Significant?

Mougey, Ruth

doi:10.1093/labmed/17.3.132

Lab Med

1986

DOI: 10.1093/labmed/17.3.132

|View full text |Cite

Are HTLA Antibodies Clinically Significant?

Ruth Mougey

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A Case of Anti-JMH Antibody with High-Titer, Low-Avidity Characteristics: The First Case in Korea

Kim

Hong

Kim

et al. 2017

KJBT

View full text Add to dashboard Cite

Anti-John Milton Hagen (JMH) is a high-titer, low-avidity (HTLA) antibody against the high frequency red blood cell (RBC) antigen JMH. It occurs very rarely and has not yet been reported in Korea. Here, we report a case of anti-JMH antibody identified in a 92-year-old man without previous blood transfusion history, who had been hospitalized with pneumonia. The patient's hemoglobin level was reduced to 7.6 g/dL on the 35th day of hospitalization, requiring RBC transfusion. Antibody identification test revealed antibodies that showed pan-reactivity to all panel cells at the antiglobulin phase. A titration test confirmed that it was a HTLA antibody. He was given one least-incompatible unit of RBC without any adverse events, and his hemoglobin level increased to 9.3 g/dL. The patient's sample was referred to a reference laboratory and the antibody was identified as anti-JMH. He was successfully transfused with 6 additional units of least-incompatible RBCs without complication. HTLA antibodies against high frequency antigens, such as anti-JMH, are less likely to cause significant destruction of transfused antigen positive RBCs. However, identifying the specificity of these antibodies is necessary to appropriately understanding the clinical significance of the antibody, detecting other clinically important alloantibodies that may coexist, and determining the appropriate blood for transfusion.

show abstract

A Case of Anti-JMH Antibody with High-Titer, Low-Avidity Characteristics: The First Case in Korea

Kim

Hong

Kim

et al. 2017

KJBT

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Are HTLA Antibodies Clinically Significant?

Cited by 1 publication

References 0 publications

A Case of Anti-JMH Antibody with High-Titer, Low-Avidity Characteristics: The First Case in Korea

A Case of Anti-JMH Antibody with High-Titer, Low-Avidity Characteristics: The First Case in Korea

Contact Info

Product

Resources

About